Printer Friendly

MERCK FILES FOR FDA REVIEW OF THREE NEW PRODUCTS

 WHITEHOUSE STATION, N.J., Jan. 25 /PRNewswire/ -- Merck & Co., Inc. (NYSE: MRK) recently began the U.S. regulatory review process for a new vaccine and new forms of two existing pharmaceutical products, the company announced today.
 The company filed with the Food and Drug Administration a Product License Application for Varivax(R), a vaccine for chickenpox, and New Drug Applications for an over-the-counter form of Merck's ulcer medication Pepcid(R) (famotidine), and a once-a-day glaucoma treatment Timoptic-XE(R) (timolol maleate in Gelrite).
 The Merck Vaccine Division will market Varivax and the U.S. Human Health Division of Merck will market Timoptic-XE.
 Johnson & Johnson-Merck Consumer Pharmaceuticals Co., a joint venture of Merck and Johnson & Johnson that markets the antacid Mylanta(R), will sell the O-T-C preparation of Pepcid.
 Earlier, Merck announced submission of an NDA for Roxiam(R) (remoxipride), a medication for the treatment of acute and chronic schizophrenia.
 /delval/
 -0- 1/25/93
 /CONTACT: Roy Walker of Merck, 215-652-6681/
 (MRK)


CO: Merck & Co., Inc.; U.S. Food and Drug Administration ST: New Jersey IN: MTC SU:

CC -- PH032 -- 8615 01/25/93 14:46 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 25, 1993
Words:185
Previous Article:CHAIRMAN SUFFERS STROKE AFTER SUCCESSFULLY CONCLUDING LABOR NEGOTIATIONS IN ITALY
Next Article:CYTOPROBE SUBSIDIARY ICP ENTERS INTO AGREEMENT WITH MEDYS
Topics:


Related Articles
MEDIMMUNE'S CEO REVIEWS RECENT DEVELOPMENTS
ROYCE LABORATORIES, INC. HAS FILED APPLICATIONS (ANDAs) FOR THREE NEW PRODUCTS
CYTOGEN SUBMITS QUADRAMET(TM) NEW DRUG APPLICATION TO FDA
QUADRAMET(TM) NEW DRUG APPLICATION FILED BY FDA
MERCK FILES NEW DRUG APPLICATION FOR PROTEASE INHIBITOR CRIXIVAN(R)
FDA Approves Barr Laboratories' Generic Coumadin
CYTOGEN Receives FDA Clearance For Quadramet

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters